An Investigation On Novel Combination For Diabetic Neuropathy
Main Article Content
Abstract
Diabetes is a multifaceted metabolic illness. When it is a chronic ailment, it severely damages several organs, including the kidneys, heart, eyes, blood arteries, and nerves. This further leads to difficulties with the macro and microvascular systems. Although there are currently enough medications to manage diabetes, there is a significant danger and death rate associated with the disease. One of the biggest problems facing medical and healthcare professionals is the reported partial relief and ongoing pain of their patients. A parallel epidemic of complications from diabetes and prediabetes has been brought on by the global epidemics of these conditions.While the last ten years have seen a significant advancement in our knowledge of the intricacies of diabetic neuropathy, the unique processes behind neuropathy in type 1 and type 2 diabetes are still unknown. To effectively treat and prevent diabetic neuropathy, further research on the disease's pathophysiology will be essential. People with diabetic peripheral neuropathy (DPN) have a much lower quality of life when they have painful diabetic neuropathy. The development of tolerance is a constraint and the efficacy of currently available pharmaceutical medicines is restricted. We shall talk about an Investigation on Novel Combination for Diabetic Neuropathy in this paper.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Pickup J, Wilham G. Epidemiology of diabetes. In: Guikshank K, ed. Textbook of diabetes. New York: Blackwell Science, 1991.
Bajaj M, Banerji M A. Type 2 diabetes in South Asians: a pathophysiologic focus on the Asian Indian epidemic. CurrDiab Rep 20044213–218.
Ashok S, Ramu M, Deepa R.et al Prevalence of neuropathy in type 2 diabetes patients attending diabetes center in South India. J Assoc Physicians India 200250546–550.
Levitt N S, Stansberry K B, Wychanck S.et al Natural progression of autonomic neuropathy and autonomic function tests in a cohort of IDDM. Diabetes Care 199619751–754.
Rathmann W, Ziegler D, Jahnke M.et al Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabetes Med 199310820–824.
Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers 2019; 5: 42.
Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol 2021; 17: 400–420.
Sasaki H, Kishimoto S. Diagnostic strategy for diabetic polyneuropathy: Focus on nerve fiber type and magnetic resonance neurography. J Diabetes Investig 2021; 12: 140–142.
Selvarajah D, Kar D, Khunti K, et al. Diabetic peripheral neuropathy: advances in diagnosis and strategies for screening and early intervention. Lancet Diabetes Endocrinol 2019; 7: 938–948.
Kamiya H, Shibata Y, Himeno T, et al. Point-of-care nerve conduction device predicts the severity of diabetic polyneuropathy: a quantitative, but easy-to-use, prediction model. J Diabetes Investig 2021; 12: 583–591.
Boulton A.J., Malik R.A., Arezzo J.C., Sosenko J.M. (2004) Diabetic somatic neuropathies. Diabetes Care 27: 1458–1486.
Dyck P.J., Norell J.E., Tritschler H., Schuette K., Samigullin R., Ziegler D., et al. (2007) Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 30: 2619–2625.
Sorensen L., Molyneaux L., Yue D.K. (2006b) The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 29: 883–887.
Scholz, J., Finnerup, N. B., Attal, N., Aziz, Q., Baron, R., Bennett, M. I., et al. (2019). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain 160, 53–59. doi: 10.1097/j.pain.0000000000001365.
Rosenberger, D. C., Blechschmidt, V., Timmerman, H., Wolff, A., and Treede, R. D. (2020). Challenges of neuropathic pain: focus on diabetic neuropathy. J. Neural Transm. (Vienna) 127, 589–624. doi: 10.1007/s00702-020-02145-7.
A.J.M. Boulton Diabetic neuropathy: is pain God’s greatest gift to mankind Semin. Vasc. Surg., 25 (2012), pp. 61-65, 10.1053/J.SEMVASCSURG.2012.04.009.
Z. Qureshi, M.N. Ali, M. Khalid an insight into potential pharmacotherapeutic agents for painful diabetic neuropathy J. Diabetes Res., 2022 (2022), 10.1155/2022/9989272.
C.M. Casellini, A.I. Vinik Recent advances in the treatment of diabetic neuropathy Curr. Opin. Endocrinol. Diabetes, 13 (2006), pp. 147-153, 10.1097/01.MED.0000216963. 51751.BE.
Papanas N., Ziegler D. Prediabetic neuropathy: does it exist? Current diabetes reports. 2012;12(4):376–383.
Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. (2010) 33:2285–93. doi: 10.2337/dc10-1303
Himeno T, Kamiya H, Nakamura J. Diabetic polyneuropathy: progress in diagnostic strategy and novel target discovery, but stagnation in drug development. J Diabetes Investig 2020; 11: 25–27.
Chen Z, Miao F, Paterson AD, Lachin JM, Zhang L, Schones DE, Wu X, Wang J, Tompkins JD, Genuth S, Braffett BH, Riggs AD, Natarajan R; DCCT/EDIC Research Group. Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort. Proc Natl AcadSci USA. 2016;113(21):E3002–E3011.
Hamel J, Logigian EL. Acute nutritional axonal neuropathy. Muscle Nerve. 2018;57(1):33–39.
Wada J, Makino H. Innate immunity in diabetes and diabetic nephropathy. Nat Rev Nephrol. 2016;12(1):13–26.
Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert OpinPharmacother. 2014;15(18):2721–2731.
Hardy T, Sachson R, Shen S, Armbruster M, Boulton AJ: Does treatment with duloxetine for neuropathic pain impact glycemic control? Diabetes Care 2007; 30: 21– 26.
Rowbotham MC, Goli V, Kunz NR, Lei D: Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 2004; 110: 697– 706.
Davies PS, Galer BS: Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004; 64: 937– 947.
Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR: Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain 1999; 81: 135– 145.
Rauck RL, Shaibani A, Biton V, Simpson J, Koch B: Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study. Clin J Pain 2007; 23: 150– 158.
Shaibani A, Fares S, Selam JL, Arslanian A, Simpson J, Sen D, Bongardt S: Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain 2009; 10: 818– 828.
Gilron I, Coderre TJ: Emerging drugs in neuropathic pain. Expert OpinEmerg Drugs 2007; 12: 113– 126.
Jacobsen, A. B. et al. The most sensitive nerves and parameters in electrodiagnosis of polyneuropathies. Clin. Neurophysiol. 127(3), e36 (2016).
Dyck, P. J., Carter, R. E. & Litchy, W. J. Modeling nerve conduction criteria for diagnosis of diabetic polyneuropathy. Muscle Nerve 44(3), 340–345 (2011).
Ganong, W. F. Lehrbuch der MedizinischenPhysiologie 4th edn. (Springer, 1979).
Buchner, H., Schönlau, L. & Ferbert, A. Neurografie des N. Suralis. KlinischeNeurophysiologie 49, 188–207 (2018).
Koo, T. K. & Li, M. Y. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J. Chiropr. Med. 15(2), 155–163 (2016).
Vinik A., Richardson D. Erectile dysfunction in diabetes: pills for penile failure. Clinical Diabetes. 1998;16(3):108–109.
Rendell M.S., et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Jama. 1999;281(5):421–426.
Enzlin P., et al. Diabetes mellitus and female sexuality: a review of 25 years’ research. Diabetic Medicine. 1998;15(10):809–815.
Shaw J., et al. A randomised controlled trial of topical glycopyrrolate, the first specific treatment for diabetic gustatory sweating. Diabetologia. 1997;40(3):299–301.
Weintraub MI, Herrmann DN, Smith AG, Backonja MM, Cole SP. Pulsed electromagnetic fields to reduce diabetic neuropathic pain and stimulate neuronal repair: a randomized controlled trial. Arch Phys Med Rehabil 2009; 90:1102–1109.
Garrow AP, Xing M, Vere J, Verrall B, Wang L, Jude EB. Role of acupuncture in the management of diabetic painful neuropathy (DPN): a pilot RCT. Acupunct Med 2014; 32:242–249.
Allet L, Srmand S, de Bie RA, et al. The gait and balance of patients with diabetes can be improved: a randomised controlled trial. Diabetologia 2010; 53:458–466.
Didangelos T, Karlafti E, Kotzakioulafi E, et al. Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial. Nutrients 2021; 13:395
Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol 2021; 78:687–698.
Bril V, Tomioka S, Buchanan RA, Perkins BA; mTCNS Study Group. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med 2009; 26:240–246.
Abbott CA, Malik RA, van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34:2220–2224
Pop-Busui, R., K.A. Sullivan, C. van Huysen, L. Bayer, X. Cao, R. Towns, M.J. Stevens, 2001. Depletion of taurine in experimental diabetic neuropathy: Implications for nerve metabolic, vascular and functional deficits. Exp. Neurol., 168: 259-272.
Stuart, C.A., S. Sherwin, T.A. Bruce, R. Freeman and B. Victor et al., 2000. Polyneuropathy: A randomized controlled trial growth factor in patients with diabetic polyneuropathy. JAMA., 284: 2215-2221.